NDAINJECTIONINJECTABLE
Approved
Oct 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
PROHANCE MULTIPACK (gadoteridol) by Bracco is magnetic resonance contrast activity [moa]. First approved in 2003.
Drug data last refreshed 2d ago
Mechanism of Action
Magnetic Resonance Contrast Activity
Pharmacologic Class:
Paramagnetic Contrast Agent
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study
Started Aug 2007
165 enrolled
Brain Metastases
Why This Matters for Your Career
Worked on PROHANCE MULTIPACK at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.